Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1

Thrombosis and Haemostasis
Laurent GorinBernard Charbonnier

Abstract

In patients with atrial fibrillation (AF) and an intermediate risk of stroke (CHADS2 score =1), available evidence from clinical trials is inconclusive and the present guidelines for the management of AF indicate that the choice between oral anticoagulant and aspirin in these patients is open. Our goal was to evaluate whether, in patients with AF and only one moderate risk factor for thromboembolism, treatment with an oral anticoagulant is appreciably more beneficial than treatment with an antiplatelet agent. Among 6,517 unselected patients with AF, 1,012 of them (15.5%) had a CHADS2 score of 1 and were liable to treatment with an antiplatelet agent or an anticoagulant. An oral anticoagulant was prescribed for 606 patients (59.9%) and an antiplatelet agent or no antithrombotic treatment for 406 (40.1%). During follow-up (median=793 days, interquartile range=1,332 days), 105 deaths (10.4%) and 19 strokes (1.9%) were recorded. The administration of an anticoagulant was associated with a lower rate of events (relative risk=0.42, 95% confidence interval 0.29-0.60, p<0.0001) than when no anticoagulant was prescribed. Results remained similar after adjustment for age and other confounding factors. In contrast, prescription of an anti...Continue Reading

Citations

Sep 24, 2013·Australian Critical Care : Official Journal of the Confederation of Australian Critical Care Nurses·Caleb FergusonPatricia M Davidson
Dec 22, 2012·European Heart Journal·Gregory Y H Lip
Mar 30, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Ron PistersRobert G Tieleman
May 20, 2011·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Jonas Bjerring OlesenDeirdre A Lane
Dec 17, 2011·International Journal of Clinical Practice·T S Potpara, G Y H Lip
May 27, 2011·Thrombosis and Haemostasis·Isla M OgilvieGregory Y H Lip
May 10, 2012·Journal of Blood Medicine·Manish B Jhawar, Greg Flaker
Oct 23, 2010·Drugs & Aging·Jonathan Mant, Duncan Edwards
Dec 14, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Alena Shantsila, Gregory Y H Lip
May 21, 2013·European Journal of Internal Medicine·Gualberto GussoniUNKNOWN ATA-AF Steering Committee and Investigators
Sep 3, 2010·Der Internist·H VöllerD Westermann
May 4, 2011·Current Atherosclerosis Reports·Sharon Poisson, S Claiborne Johnston
Mar 25, 2014·Heart Failure Clinics·Sudarone Thihalolipavan, Daniel P Morin
Jun 29, 2013·The Canadian Journal of Cardiology·Richard P WhitlockMatthew Danter
Sep 11, 2012·Best Practice & Research. Clinical Haematology·Ron Hoffman, Benjamin Brenner
Nov 4, 2011·Heart & Lung : the Journal of Critical Care·Kathleen Hickey
Jul 13, 2011·The American Journal of Medicine·Raffaele De Caterina, Elaine M Hylek
Jun 21, 2011·Revista española de cardiología·Amitava BanerjeeGregory Y H Lip
Sep 3, 2010·Journal of the Neurological Sciences·Nadzeya Kuzniatsova, Gregory Y H Lip
Mar 17, 2015·Journal of the American College of Cardiology·Gregory Y H LipTorben Bjerregaard Larsen
Jul 27, 2010·Journal of Cardiovascular Electrophysiology·Daniela PoliDeirdre Lane
Jan 17, 2012·Clinical Cardiology·Gregory Y H Lip
Jan 17, 2012·Clinical Cardiology·Jonas Bjerring OlesenGregory Y H Lip
Oct 30, 2010·Journal of Thrombosis and Haemostasis : JTH·T P Van StaaG Y H Lip
Aug 4, 2011·Journal of Thrombosis and Haemostasis : JTH·G Y H Lip
Jul 21, 2015·Progress in Cardiovascular Diseases·Sudarone Thihalolipavan, Daniel P Morin
Jun 4, 2011·Expert Opinion on Pharmacotherapy·Vicente Bertomeu-GonzálezUNKNOWN investigators of the CARDIOTENS2 study

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.